Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Clinical trial NCT06564623 · RECRUITING
Trial details
- NCT number
- NCT06564623
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-27
- Primary completion
- 2029-03-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.